Explore every episode of the podcast The Journal of Clinical and Aesthetic Dermatology

Dive into the complete episode list for The Journal of Clinical and Aesthetic Dermatology. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

	Title	Pub. Date	Duration
	Stan Tolkachjov, MD: Importance of Early Recognition and Treatment of GPP	29 oct. 2026	00:08:46
Send us Fan Mail Dr. Tolkachjov discusses generalized pustular psoriasis (GPP) as a distinct, potentially severe inflammatory disease characterized by widespread sterile pustules, erythema, systemic symptoms, and recurrent flares. He reviews the role of dysregulated IL-36 signaling and downstream neutrophilic inflammation in GPP pathogenesis, and explains how targeting this pathway with spesolimab has changed the treatment approach. Dr. Tolkachjov also highlights the importance of distinguishing GPP from other pustular eruptions and recognizing presentations associated with pregnancy or corticosteroid withdrawal. Beyond acute flare management, he emphasizes the burden of symptoms between flares and the importance of ongoing treatment strategies aimed at reducing future recurrences and hospitalizations.
	Victoria Werth, MD: Sustained Response With Litifilimab in CLE	20 oct. 2026	00:06:22
Send us Fan Mail Dr. Werth reviews 52-week findings from the phase 2 AMETHYST study of litifilimab in patients with moderate-to-severe cutaneous lupus erythematosus (CLE). She highlights the rapid onset of response observed during the randomized portion of the trial and explains that patients who switched from placebo to litifilimab at Week 24 showed improvement within several weeks and subsequently approached the responses seen in patients treated from the outset. Participants who received litifilimab throughout the study continued to improve across multiple clinical endpoints through Week 52, with maintenance of previously achieved responses. Dr. Werth also notes that treatment was generally well tolerated, with no new safety signals, and that the ongoing phase 3 trial will further evaluate litifilimab’s efficacy and safety in CLE.
	Shannon Trotter, DO: Clinical Considerations for Severe Alopecia Areata	16 oct. 2026	00:09:07
Send us Fan Mail Dr. Trotter discusses necessary clinical considerations and practical use cases for the treatment of severe alopecia areata with treatments such as deuruxolitinib. She highlights the importance of systemic therapy in patients with severe alopecia areata due primarily to lack of spontaneous remission and risk of disease progression. Additionally, Dr. Trotter identifies best use cases for deuruxolitinib, emphasizes the importance of patient severity assessments such as the Alopecia Areata Scale, and suggests performing regular safety checks to continuously monitor concomitant conditions and inhibitors.
	Saakshi Khattri, MD: Evaluating the Newest Data in CLE	14 oct. 2026	00:05:38
Send us Fan Mail Dr. Khattri looks at the 52-week findings from the ongoing phase 2/3 AMETHYST trial evaluating litifilimab in cutaneous lupus erythematosus (CLE), which were presented at the EADV Congress 2026. She notes that there are currently no FDA-approved targeted therapies for CLE, a disease that can cause permanent scarring, dyspigmentation, and scarring alopecia. Litifilimab, a monoclonal antibody that targets BDCA2, demonstrated continued improvement through 52 weeks rather than plateauing, according to Dr. Khattri. She emphasizes the importance of durability of treatment for patients with CLE who have had an inadequate response to first-line therapy.
	Nicholas Brownstone, MD: Achieving Long-Term Success in Psoriasis	09 oct. 2026	00:09:44
Send us Fan Mail Dr. Brownstone discusses the place of risankizumab in the psoriasis and psoriatic arthritis treatment landscape. He discusses risankizumab’s durable response, infrequent dosing, and favorable long-term and short-term safety profiles. Dr. Brownstone references the UltIMMa-1 (NCT02684370) and UltIMMa-2 (NCT02684357) trials, which demonstrated the superior efficacy of risankizumab vs placebo and ustekinumab in this patient population. Additionally, he cites a recent anecdotal case detailing one of his patient’s positive experiences with risankizumab.
	James Del Rosso, DO: JCAD September 2026 Issue Highlights	07 oct. 2026	00:16:17
Send us Fan Mail Dr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2026 issue of JCAD.
	Claudia Günther, MD, PhD: Analysis of Phase 2 CLE Trial With Litifilimab	06 oct. 2026	00:05:58
Send us Fan Mail Dr. Günther discusses her poster from the European Academy of Dermatology and Venereology Congress 2026 on transcriptomic analyses of the phase 2 LILAC trial Part B. The study examined how litifilimab affects the underlying biology of cutaneous lupus erythematosus (CLE). RNA sequencing demonstrated broad immune dysregulation in patients with CLE and showed that treatment with litifilimab shifted numerous disease-associated genes toward expression patterns observed in healthy individuals, including genes involved in type I interferon signaling and other inflammatory pathways. Dr. Günther also reviews 5 molecular endotypes identified by baseline gene expression. Clinical improvement was observed across the endotypes studied, supporting a treatment effect across biologically diverse groups of patients with CLE.
	Joseph Fakhoury, MD: Special Considerations in Severe Alopecia Areata	14 sept. 2026	00:07:28
Send us Fan Mail Dr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia Tool (SALT) score of 20 to 49 and outlined patient populations who could benefit from treatment with deuruxolitinib.
	Raj Chovatiya, MD, PhD, MSCI: Intravenous vs Subcutaneous GPP Therapy	01 sept. 2026	00:05:43
Send us Fan Mail Dr. Chovatiya reviews generalized pustular psoriasis (GPP) as a distinct, potentially life-threatening inflammatory dermatosis characterized by acute flares and periods of relative quiescence. He highlights the diagnostic challenges in differentiating GPP from plaque psoriasis and other pustular disorders, as well as the central role of interleukin (IL)-36 pathway dysregulation in driving neutrophilic inflammation. He also reviews the use of intravenous therapy for rapid management of active flares and subcutaneous therapy for long-term flare prevention, and how these formulations may be incorporated across the disease course to support both acute control and ongoing GPP management.
	James Del Rosso, DO: JCAD August 2026 Issue Highlights	31 août 2026	00:22:22
Send us Fan Mail Dr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2026 issue of JCAD.
	Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites	06 août 2026	00:05:25
Send us Fan Mail Dr. Cohen discusses the treatment of psoriasis in high-impact sites. He outlines how to approach these special considerations and provides treatment options, including the utilization of biologics like risankizumab. He also reviews considerations for unique cases such as nail psoriasis and palmoplantar psoriasis.
	Jason Hawkes, MD, MS: The IL-36 Inflammatory Pathway and Generalized Pustular Psoriasis	05 août 2026	00:11:28
Send us Fan Mail Ahead of National Generalized Pustular Psoriasis (GPP) Awareness Day, Dr. Hawkes gives an overview of the distinct clinical and immunologic features of GPP, emphasizing how this rare, life-threatening disease differs from plaque psoriasis in both presentation and underlying pathophysiology. He highlights the central role of interleukin-36 (IL-36) dysregulation in GPP, explains why therapies developed for plaque psoriasis often do not provide adequate control of the disease, and outlines the rationale for IL-36 receptor inhibition as a targeted treatment strategy. Dr. Hawkes also discusses the practical use of spesolimab for both acute flares and long-term maintenance, including patient selection, dosing approaches, and the rapid clinical responses observed with intravenous therapy.
	James Del Rosso, DO: JCAD July 2026 Issue Highlights	31 juil. 2026	00:20:55
Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the July 2026 issue of JCAD.
	Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment	01 juil. 2026	00:07:36
Send us Fan Mail Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.
	James Del Rosso, DO: JCAD June 2026 Issue Highlights	29 juin 2026	00:13:28
Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.
	Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis	04 juin 2026	00:06:04
Send us Fan Mail Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.
	James Del Rosso, DO: JCAD May 2026 Issue Highlights	29 mai 2026	00:20:00
Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.
	Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis	15 mai 2026	00:07:28
Send us Fan Mail Bruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober emphasizes risankizumab's effectiveness in patients with psoriatic arthritis and those with low body surface area involvement, often making it a first-line systemic treatment for psoriasis.
	James Del Rosso, DO: JCAD April 2026 Issue Highlights	30 avr. 2026	00:22:07
Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.
	James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus	28 avr. 2026	00:27:02
Send us Fan Mail James Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which showed a significant reduction in skin disease activity in patients with CLE by Week 16.
	James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis	24 avr. 2026	00:18:18
Send us Fan Mail James Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA). They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with antifungals and antibiotics without improvement. After initiating bimekizumab, she achieved complete resolution of all nail and joint symptoms within 3 months. In another case, a 63-year-old woman with nail psoriasis and symptomatic PsA experienced near-complete relief of pain, joint stiffness, and loss of hand dexterity within one month of her first dose, with full nail clearance by 3 months. The discussion emphasizes the challenges of diagnosing nail psoriasis, the significant psychosocial burden it imposes, and the potential for accelerated clearance with dual interleukin (IL)-17A and IL-17F inhibition even in the absence of cutaneous psoriatic involvement. Dr. Del Rosso is with JDR Dermatology Research, Las Vegas, Nevada and Touro University Nevada, Henderson, Nevada. Dr. Dasilva is with Forefront Dermatology, Virginia Beach, Virginia and Eastern Virginia Medical School, Norfolk, Virginia. Dr. Litchman is with Vivida Dermatology, Las Vegas, Nevada and Touro University Nevada, Henderson, Nevada.
	James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD	01 avr. 2026	00:25:33
Send us Fan Mail James Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemolizumab, experiencing significant improvement in itch and facial erythema within 2 months. The discussion emphasizes the importance of individualized treatment and the evolving therapeutic landscape for AD.
	James Del Rosso, DO: JCAD March 2026 Issue Highlights	30 mars 2026	00:18:03
Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.
	Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata	17 mars 2026	00:07:51
Send us Fan Mail Ted Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of effect over time. He emphasizes that this durability is crucial, as patients are often most afraid of losing newly regrown hair.
	James Del Rosso, DO: JCAD February 2026 Issue Highlights	26 févr. 2026	00:24:22
Send us Fan Mail James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.
	James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment	19 févr. 2026	00:19:29
Send us Fan Mail James Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and avoid constantly cycling through treatments.
	Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata	19 févr. 2026	00:06:02
Send us Fan Mail Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus kinase inhibitors.
	Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis	17 févr. 2026	00:08:39
Send us Fan Mail Graham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearing. After 1 year of treatment, the patient had only a small area of plaques.
	James Del Rosso, DO: JCAD January 2026 Issue Highlights	30 janv. 2026	00:22:36
Send us Fan Mail James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.
	Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment	22 janv. 2026	00:05:18
Send us Fan Mail Dr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.
	Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata	02 déc. 2025	00:04:35
Send us Fan Mail Dr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.
	James Del Rosso, DO: JCAD November 2025 Issue Highlights	20 nov. 2025	00:20:01
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.
	Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis	13 nov. 2025	00:21:52
Send us Fan Mail Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.
	James Del Rosso, DO: JCAD October 2025 Issue Highlights	30 oct. 2025	00:18:53
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2025 issue of JCAD.
	David G. Cotter, MD, PhD: The Ideal Patient Candidate for Deuruxolitinib for Patients with Alopecia Areata	16 oct. 2025	00:01:45
Send us Fan Mail Dr. Cotter discusses providing rapid hair regrowth in patients with alopecia areata.
	David G. Cotter, MD, PhD: Utilizing the 31-gene Expression Profile Test in Patients with Melanoma	09 oct. 2025	00:08:53
Send us Fan Mail Dr. Cotter discusses results of an expert consensus panel of the 31-gene expression profile test for patients with Melanoma.
	David G. Cotter, MD, PhD: Providing Regrowth of Hair in Patients with Alopecia Areata	22 sept. 2025	00:06:33
Send us Fan Mail Dr. Cotter discusses providing effective treatment for patients with alopecia areata
	James Del Rosso, DO: JCAD September 2025 Issue Highlights	01 sept. 2025	00:20:38
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2025 issue of JCAD.
	James Del Rosso, DO: JCAD August 2025 Issue Highlights	26 août 2025	00:19:21
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2025 issue of JCAD.
	JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea	23 juin 2025	00:08:55
Send us Fan Mail Dr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.
	James Del Rosso, DO: JCAD June 2025 Issue Highlights	20 juin 2025	00:16:21
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2025 issue of JCAD.
	Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis	27 mai 2025	00:24:09
Send us Fan Mail In this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
	James Del Rosso, DO: JCAD May 2025 Issue Highlights	22 mai 2025	00:15:01
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2025 issue of JCAD.
	James Del Rosso, DO: JCAD April 2025 Issue Highlights	16 avr. 2025	00:17:58
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2025 issue of JCAD.
	James Del Rosso, DO: JCAD February 2025 Issue Highlights	31 janv. 2025	00:12:20
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2025 issue of JCAD.
	JCAD Dialogues and Reviews: Highlighting a Vitiligo Roundtable Discussion in JCAD	31 janv. 2025	00:03:24
Send us Fan Mail Dr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.
	JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events	28 janv. 2025	00:07:57
Send us Fan Mail Dr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.
	James Del Rosso, DO: JCAD January 2025 Issue Highlights	03 janv. 2025	00:10:09
Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2025 issue of JCAD.
	James Del Rosso, DO: Dermatology Year in Review 2024	17 déc. 2024	00:14:19
Send us Fan Mail Dr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.
	JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea	21 nov. 2024	00:05:33
Send us Fan Mail Dr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.

About Methodology Contact Support me Privacy Policy Legal Notice